Alan Rigby Email & Phone Number

Montreal, Ca

At Epitopea we know that better cancer therapies are needed to transform patient responses and their lives. Epitopea is the global leader in exploiting a novel class of untapped, aberrantly expressed tumor-specific antigens (aeTSAs) or CryptigenTM TSAs that are shared across multiple patients with the same tumor type. We leverage these differentiated aeTSAs to rapidly advance the development of accessible, off-the-shelf cancer RNA immunotherapies that we believe will significantly impact patients’ lives.

New York, New York, Us

New York, New York, Us

New York, New York, Us

HiberCell is 'The Tumor Dormancy Company' with a focus on targeting dormant disseminated tumor cells to prevent or delay cancer relapse and metastasis.

At Exarta I worked closely with pioneering academic founders, Drs. Brent Stockwell and Xuejun Jiang to help build and validate transformative medicines that modulate the biology of ferroptosis and in doing so course correct the pathogenesis of cancer resistance and neurodegenerative disease.

Us

Us

Boston, Ma, Us

Director of Drug Discovery & Target Validation Program

Boston, Ma, Us

Boston, Ma, Us

Accelerating Discovery in the Center for Vascular Biology

Boston, Ma, Us

NewCo opportunity

Boston, Ma, Us